Introduction to Intera 3000 Pump and Hepatic Artery Infusion (HAI) Therapy

The goal of HAI therapy is simple in concept, deliver a concentrated chemotherapeutic drug (floxuridine) directly to tumors that have spread to the liver (clinical term is metastasized) from the origin of the cancer in the gastrointestinal tract.

The Model 3000 implantable pump has been used for over 25 years to target liver metastases by delivering a high concentration of floxuridine directly to the liver.  Explore the links below to review some of the published clinical evidence on the use of the Intera 3000 with floxuridine to treat liver metastases that have spread from gastrointestinal cancers.

HAI Therapy Clinical Evidence

32.8

Month survival; 2 Month
systemic chemo only

47%

of initially ineligible patients
converted to resection

60%

Increase in
10-Year Overall Survival

Use of systemic chemotherapy in addition to floxuridine will increase patient toxicity and should be monitored by the treating physician. Publications relating to floxuridine are for educational purposes only.

© Copyright 2021 Intera Oncology. All Right Reserved Designed by Medtech Momentum